(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 July 2019 (25.07.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/143824 A1

(51) International Patent Classification:
A61K 31/19 (2006.01)

(21) International Application Number:
PCT/US2019/014022

(22) International Filing Date:
17 January 2019 (17.01.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/619,062	18 January 2018 (18.01.2018)	US
62/668,092	07 May 2018 (07.05.2018)	US
62/683,325	11 June 2018 (11.06.2018)	US

(71) Applicant: **AEVI GENOMIC MEDICINE, INC.** [US/US]; 435 Devon Park Drive, Suite 715, Wayne, Pennsylvania 19087 (US).

(72) Inventors: **LEYSSENS, Tom**; Sint-Norbertusstraat 10, 1090 Jette (BE). **COUCH, Richard Alan**; 777 Woodleave Road, Bryn Mawr, Pennsylvania 19010 (US). **GUILLOT, Michael Paul René**; Avenue des Combattants, 96, 1340 Ottignies (BE). **HARMSEN, Bram**; Angelgartenstraße 70, 64846 Groß-Zimmern (DE). **BAILEY, Thomas R.**; 217 Amanda Lane, Phoenixville, Pennsylvania 19460 (US). **APPELMANS, Martin**; Avenue général de Longueville, n °22, Box 4, 1150 Brussels (BE).

(74) Agent: **BAUR, Amelia Feulner** et al.; MCNEILL BAUR PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: SOLID FORMS OF FASORACETAM

ORTEPof R-fasoracetam:PABA cocrystal




Figure 13

(57) Abstract: The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

WO 2019/143824 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*